Risk factors of Charcot Neuroarthropathy Development in Patients with Type 2 Diabetes

Abstract

Aim:

Charcot neuroarthropathy is a very rare form of diabetic foot syndrome occurring among others in patients with diabetes mellitus. Charcot neuroarthropathy leads to bone tissue destruction and may result in foot amputation. The aim of the study was to identify risk factors of Charcot neuroarthropathy occurrence in patients with diabetic foot and type 2 diabetes.

Materials:

The study included 144 patients with type 2 diabetes; 33 with Charcot neuroarthropathy and 111 with diabetic foot of neuropathic origin without neuroarthropathy. The study was perform in Gastroenterology and Metabolic Diseases Department, Medical University of Warsaw, Poland.

Results:

The regression analysis showed that Charcot neuroarthropathy occurrence risk factors were: male gender (OR=4.94, 95% CI:1.63–15.03, p=0.003), age (OR=0.92, 95% CI:0.87–0.96, p=0.0001), diabetic foot duration (OR=1.19, 95% CI:1.08–1.32, p=0.00002) and height (OR=1.078, 95% CI:1.019–1.140, p=0.007). A positive effect on Charcot neuroarthropathy presence was exerted by body weight (OR=1.027, 95% CI:1.003–1.051, p=0.03) and hips circumference (OR=1.034, 95% CI:0.997–1.072, p=0.04).

Conclusions:

The existence of the specific factors influencing Charcot neuroarthropathy development may result in earlier identification of patients at risk of its development. There is a necessity to take special care for patients prone to develop Charcot neuroarthropathy in order to prevent its occurrence and severe complications.

Key words

neuropathy - obesity - peripheral arterial disease

• References

• 1 Kamińska A, Bronisz A, Kamiński M et al. Cukrzycowa neuroartropatia Charcota. Diabetologia Doświadczalna i Kliniczna 2004; 3: 175-179
• 2 Nagarkatti DG, Banta JV, Thomson JD. Charcot arthropathy in spina bifida. J Pediatr Orthop 2000; 20: 82-87
• 3 McKay DJ, Sheehan P, DeLauro TM et al. Vincristine-induced neuroarthropathy (Charcot’s joint). J Am Podiatr Med Assoc 2000; 90: 478-480
• 4 Sanders LJ, Frykberg RG. Diabetic neuropathic osteoarthropathy: the Charcot foot. In: Fryberg RG. eds. The High Risk Foot in Diabetes Mellitus. New York: Churchill Livingstone; 1991: 297-338
• 5 Petrova NL, Foster AVM, Edmonds ME et al. Difference in presentation of Charcot osteoarthropathy in type 1 compared with type 2 diabetes. Diabetes Care 2004; 27: 5
• 6 Rajbhandari SM, Jenkins RC, Davies C et al. Charcot neuroarthropathy in diabetes mellitus. Diabetologia 2002; 45: 1085-1096
• 7 Stuck RM, Sohn MW, Budiman-Mak E et al. Charcot Arthropathy Risk Elevation in the Obese Diabetic Population. The American Journal of Medicine 2008; 11: 121
• 8 Jeffcoate W, Lima J, Nobrega L. The Charcot foot. Diabet Med 2000; 17: 253-258
• 9 Fabrin J, Larsen K, Holstein PE. Long-term follow up in diabetic Charcot feet with spontaneous onset. Diabetes Care 2000; 23: 796-800
• 10 Berg EE. Charcot arthropathy after acetabular fracture. J Bone Joint Surg Br 1997; 79: 742-745
• 11 Armstrong DG, Todd WF, Lavery LA et al. The natural history of acute Charcot’s arthropathy in a diabetic foot speciality clinic. Diabet Med 1997; 14: 357-363
• 12 Slowman-Kovacs SD, Braunstein EM, Brandt KD. Rapidly progressive Charcot arthropathy following minor joint trauma in patients with diabetic neuropathy. Arthritis Rheum 1990; 33: 412-417
• 13 Charcot JM. Sur quelques arthropathies qui paraissent dependre d’une lesion du cerveau ou de la mouelle epiniere. Arch Physiol Norm Patol 1868; 1: 161-178
• 14 Jeffcoate W. Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev 2008; 24: 62-65
• 15 Gouveri E, Papanas N et al. Charcot osteoarthropathy in diabetes: A brief review with an emphasis on clinical practice. World J Diabetes 2011; 5: 59-65
• 16 Sinha S, Munichoodappa C, Kozak GP. Neuroarthropathy (Charcot’s joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 1972; 51: 191-210
• 17 Saltzman CL, Hagy ML, Zimmerman B et al. How effective is intensive nonoperative initial treatment of patients with diabetes and Charcot arthropathy of the feet?. Clin Orthop Relat Res 2005; 435: 185-190
• 18 Musa HG, Ahmed ME. Associated risk factors and management of chronic diabetic foot ulcers exceeding 6 months’ duration. Diabetic Foot & Ankle. 2012: 3
• 19 Sohn MW, Todd AL, Rodney MS. Mortality Risk of Charcot Arthropathy Compared With That of Diabetic Foot Ulcer and Diabetes Alone. Diabetes Care 2009; 32: 816-821
• 20 Sohn MW, Stuck RM, Pinzur M et al. Lower-extremity amputation risk after Charcot arthropathy and diabetic foot ulcer. Diabetes Care 2010; 33: 98-100
• 21 Holzer SE, Camerota A, Martens L et. al. Costs and duration of care for Lower extremity ulcers in patients with diabetes. Clin Ther 1998; 20: 169-181
• 22 International Consensus on the Diabetic Foot and Practical Guidelines on the Management and Prevention of the Diabetic Foot 2007 . International Working Group on the Diabetic Foot/Consultative Section of the IDF. Amsterdam, the Netherlands, on DVD.
• 23 Perkins BA, Olaleye D, Zinman B et al. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24: 250-256
• 24 James WB. Classification of foot lesions in Diabetic patients. Levin and O’Neals. The Diabetic Foot 2008; 9: 221-226
• 25 Eichenholtz SN. Charcot joints. Springfield (IL): Charles C. Thomas; 1996
• 26 Leung HB, Ho YC, Wong WC. Charcot foot in a Hong Kong Chinese diabetic population. Hong Kong Med J 2009; 15: 191-195